PHASE II STUDY OF 90Y-IBRITUMOMAB TIUXETAN AND FOTEMUSTINE ASSOCIATED WITH CYTARABINE ETOPOSIDE MELPHALAN AS CONDITIONING CHEMORADIOIMMUNOTHERAPY IN PATIENTS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODGKIN) CD20+ REFRACTORY/RELAPSED WITH MINIMAL RESIDUAL PERSISTANT DISEASE PRE-AUTOLOGOUS TRANSPLANT.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Aug 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fotemustine (Primary) ; Ibritumomab tiuxetan (Primary) ; Cytarabine; Etoposide; Melphalan
Indications Hodgkin's disease; Non-Hodgkin's lymphoma
Focus Adverse reactions
Acronyms Z-FEAM

Most Recent Events

03 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight